Actively Recruiting
Phase 1 Study Evaluating Drug Interactions and Heart Effects of Fosmanogepix in Healthy Adults
Led by Basilea Pharmaceutica · Updated on 2026-10-19
42
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 1 study with approximately 42 healthy adult participants to evaluate the drug-drug interaction potential and effects on heart rhythm QTc interval of fosmanogepix, an investigational drug. The study is divided into two parts Part 1 focuses on the impact of fosmanogepixs active form, manogepix, on selected liver enzymes and QTc, while Part 2 examines manogepixs effects on specific enzymes and drug transporters. Participants will receive fosmanogepix or placebo along with probe drugs in a fixed sequence. In Part 1, a medicine cocktail is given on Days 1 and 22, with fosmanogepix or placebo administered from Days 5 to 24. Part 2 involves administration of repaglinide, rosuvastatin, and digoxin on specified days and fosmanogepix from Days 6 to 21. Fosmanogepix and placebo are given either as intravenous infusions or oral tablets, while probe drugs are oral tablets or capsules. Participants will undergo various assessments including blood tests to measure drug concentrations and evaluate heart rhythm changes via ECG. Safety is monitored through adverse event reports throughout the study, which lasts up to about 13.5 weeks in Part 1 and 12 weeks in Part 2. Researchers will measure maximum drug concentrations, exposure over time, and changes in QTc interval to understand the interaction potential and safety of fosmanogepix.
CONDITIONS
Brief Title
A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects
Research Team
T
Thomas Kaindl, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here